Antisense Therapeutics

Antisense Therapeutics is an Australian biotechnology company developing antisense oligonucleotide (ASO) therapies for the treatment of rare diseases. Its lead asset, ATL1102, is being investigated as a targeted anti-inflammatory therapy to treat Duchenne muscular dystrophy (DMD). In a positive strategic pivot, trial design was amended to a smaller Phase IIb study (n=42 vs 108) that should provide a nearer-term catalyst, if positive readouts are achieved. As a result of the reduced trial costs, the company’s cash runway is anticipated to be extended (net cash at end-June 2022 of A$19.2m) into Q4 CY23. Management envisages a need to raise funds in the mid-single digit (A$m) region, which it anticipates will fund operations to trial readouts in Q124.

Equities

Equities by Sector

Sectors

Thematics

Latest

Hybrid Air Vehicles – Redefining air travel and air freight

The humanoid revolution walking your way: How robots are stepping out of science fiction

From gold to gold miners: Extracting higher returns in the current bull run

Audiovisual

Latest

discoverIE Group – executive interview

Spotting the next big winners: UK small caps with Aberdeen’s Abby Glennie

Nabaltec – executive interview

About Edison

About Edison

Careers

Antisense Therapeutics (ASX: ANP)

Latest Insights

Antisense Therapeutics — executive interview with James Garner, chief executive officer

Research

Further insights

Healthcare Week 2023

Climate: Creating multi-trillion investment opportunities

ConsumerWatch – Looking for a sign

Molten Ventures – executive interviews

The US government and Trump: Market implications

UK consumer sectors – What did Santa bring in 2024?

Why is gold hitting new highs?

Saba Capital campaign – Your vote matters

Market outlook: What lies ahead in 2025

Borussia Dortmund – executive interviews

UK equities: A generational opportunity?

Renewable energy developers – Creating value for investors

Healthcare-focused trusts: A sector on the mend

MediaWatch – One step forward, two steps back

ConsumerWatch – Don’t look down

A net zero perspective – Investing in sustainability, technology & innovation

Banco Angolano de Investimentos (BAI) – Money-centre bank with lending optionality

The art of measurement – Challenges in metrology

Vietnam Holding – Vietnam in the global digital race

US small-cap equities – Time to shine?

MediaWatch – Encouragements and frustrations

ConsumerWatch – The times they are a-changin’

Emerging markets – Worthy of consideration

Dynam Capital at the 2024 Vietnam ESG Conference

MediaWatch – Glimpses of positivity

ConsumerWatch – Give me a reason to love you

UK stock market – Scope for further upside in UK large-cap stocks

Listed private equity – Performing a balancing act

ConsumerWatch – At least someone loves me

MediaWatch – Rinse and repeat

Outlook for 2024: Life sciences – where has the conviction gone?

South African life assurers: Where is the growth?

Deutsches Eigenkapitalforum (EKF) 2023 consumer and media

Deutsches Eigenkapitalforum (EKF) 2023 technology

Deutsches Eigenkapitalforum (EKF) 2023 financials and investment companies

Deutsches Eigenkapitalforum (EKF) 2023 industrials

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

VolitionRx – Decoding the DNA of cancer

MediaWatch – Still waiting…

ConsumerWatch – Falling into the fall

Shades of the 1970s

The long and winding road

MediaWatch – Targeting the opportunities

ConsumerWatch – Making the most of the summer

ASCO 2023 key takeaways

IFRS 17: Impact on life assurance companies

MediaWatch – Vision On

ConsumerWatch – A Spring in the step

Quantum computing: A booming industry

Critical minerals: The investment vacuum

Crypto, are you dead yet?

UK housebuilders

European equities

Listed Private Equity

Lithium’s adolescence

Battery energy storage

MediaWatch – Screening well

Vietnamese equities: Due a comeback?

Machine learning in drug development